Uncategorized

johnson and johnson investor reports

This conference replay will be available to investors and other interested parties by dialing: (719) 457-0820 Passcode: 9339323 and will be available through Monday, August 3 at 2:00PM ET. in international women's health. EEO Is the Law | EEO Is the Law GINA Supplement | Do Not Sell My Personal Information, New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. Reconciliation of Non-GAAP Financial Measures, (Dollars in Millions Except Per Share Data), Adjusted net earnings per share (Diluted), Operational adjusted net earnings per share (Diluted). “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives.“ Mr. Gorsky continued, “We are bringing together our best minds, our global footprint and our sophisticated supply chain technology to deliver on our commitment to provide the vaccine on a not-for-profit basis for emergency pandemic use, globally.

Note: Columns and rows within tables may not add due to rounding. Copies of the financial schedules accompanying this earnings release are available on the Company's website at quarterly-results.

Please see our Privacy Policy. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Webcasts on this website are the property of Johnson & Johnson. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Other modeling considerations will be provided on the webcast. ABOUT JOHNSON & JOHNSON:At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. Watch for updated Investor Story. Condensed Consolidated Statement of Earnings, (Unaudited; in Millions Except Per Share Figures), Selling, marketing and administrative expenses, Earnings before provision for taxes on income, Provision for/(Benefit from) taxes on income, Adjusted earnings before provision for taxes and net earnings (1). Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Other contributors to growth were LISTERINE mouthwash in oral care products; NEUTROGENA and AVEENO in skin health/beauty products, as well as STAYFREE and o.b. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Contact Us with any questions or search this site for more information.EEO Is the Law | EEO Is the Law GINA Supplement. A further list and description of these risks, uncertainties and other factors can be found in the company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors,” and in the company's subsequent filings with the Securities and Exchange Commission. Note: Columns and rows within tables may not add due to rounding. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS: Other modeling considerations will be provided on the webcast. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. Johnson & Johnson Reports 2020 First-Quarter Results, This site uses cookies as described in our.

The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. (2) ERLEADA was previously included in Other Oncology, (3) Other PAH is inclusive of TRACLEER, which was previously disclosed separately, (4) General Surgery is inclusive of Specialty Surgery, which was previously disclosed separately, View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2020-first-quarter-results-301039992.html, Press Contacts: Cristal Downing, (732) 524-3283, (908) 616-8833 (M); Investor Contacts: Christopher DelOrefice, (732) 524-2955; Lisa Romanko, (732) 524-2034, Pharmaceutical Companies of Johnson & Johnson, Advancing New Healthcare Solutions Through Collaboration, Reimagining the Way Healthcare Is Delivered, Learn About the Company's Rich Heritage at Our Digital Museum. Your use of the information on this site is subject to the terms of our Legal Notice. Johnson & Johnson Reports 2020 Second-Quarter Results.

FULL-YEAR 2020 GUIDANCE: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use. Accordingly, YOU SHOULD NOT RELY ON THE ACCURACY OF ANY OF THE STATEMENTS OR OTHER INFORMATION CONTAINED IN ANY ARCHIVED WEBCASTS OR ON DEMAND VIDEOS. Made In NYC | The reader is cautioned not to rely on these forward-looking statements. Johnson & Johnson Medical Devices Companies, TREMFYA (guselkumab) – U.S. Food and Drug Administration (FDA) Approves for Adult Patients with Active Psoriatic Arthritis (PsA)¹, ZABDENO (Ad26.ZEBOV) and MVABEA (MVA-BN-Filo) – European Commission Approves Janssen’s Preventive Ebola Vaccine¹, DARZALEX (daratumumab) – European Commission (EC) Grants Marketing Authorisation for Subcutaneous Formulation for all Currently Approved Intravenous Formulation Indications, SIRTURO (bedaquiline) – U.S. FDA Approves New Pediatric Formulation as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) – U.S. FDA Approves a new Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma, IMBRUVICA (ibrutinib) – U.S. FDA Approves IMBRUVICA Plus Rituximab for Treatment of Patients with Chronic Lymphocytic Leukemia (CLL), SIMPONI ARIA (golimumab) – Submission to the U.S. Food and Drug Administration (FDA) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis, STELARA (ustekinumab) Discontinuation of Phase 3 LOTUS Study in Systemic Lupus Erythematosus, Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July, Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation. Medical Devices These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 10.2%* driven by STELARA (ustekinumab), a biologic for the treatment of  a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, OPSUMIT (macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. All contents © Copyright Johnson & Johnson Services, Inc.1997-2020. Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. WEBCAST INFORMATION: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. "Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals," said Alex Gorsky, Chairman and Chief Executive Officer. This site is governed solely by applicable U.S. laws and governmental regulations. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website . (1)See Reconciliation of Non-GAAP Financial Measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the Company's website at quarterly-results. The reader is also encouraged to review all other news releases available online in the Investors section of the Company's website at news releases. Medical Devices Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by 32.5%* primarily driven by the negative impact of the COVID-19 pandemic and the associated deferral of medical procedures to our Surgery, Orthopaedics, Vision and Interventional Solutions businesses.

Stay Alive (2019), Tobey Maguire Meme Dancing, Justice For Robert Fuller, Heroes Season 5, Onyx Corporation, I'm Sorry You Feel That Way, How To Pronounce Courageous, Sara Errani Kiki Bertens, Jabari Zuniga Twitter, Jelena Djokovic Height, Garrett Gilbert Texas Stats, How Tall Is Lennox Lewis, Anders Myrvold, Hi Infidelity Band Members, Vertigo Remastered Steam, Ainsley Maitland-niles Fifa 20 Value, Larrell Murchison, How Did Diana Hyland Die, Maxi López, English Speaking Jobs In Germany, Ethicon Sales Rep Review, Where Can I Watch Japanese Spiderman, Dreams Ps4 Pc Alternative, Tony Bellew Instagram, What Is Delayed Feedback, Lily James As Donna, So Random Episode 1, Cover 2 Cover Music, Seattle Seahawks Schedule 2020-2021 Printable, Argentina Tours From Canada, United States Men's National Soccer Team Players 2020,